This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Donepezil
From Proteopedia
(Difference between revisions)
| Line 16: | Line 16: | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| - | ! | + | ! [[Donepezil]] |
| - | ! | + | ! [[Tacrine]] |
| - | ! | + | ! [[Rivastigmine]] |
| - | ! | + | ! [[Galantamine]] |
|- | |- | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
Revision as of 09:54, 30 November 2010
|
Better Known as: Aricept
- Marketed By: Eisai & Pfizer
- Major Indication: Alzheimer's Disease
- Drug Class: Acetylcholinesterase Inhibitor
- Date of FDA Approval (Withdrawn): 1996 (2008)
- 2006 Sales: $800 Million
- Why You Should Care: One of the most effective treatments for teh symptoms of Alzheimer's Disease, although no definitive proof exists as to whether to alters the progression of the disease.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| Aceylcholinesterase Inhibitor Pharmacokinetics | ||||||
|---|---|---|---|---|---|---|
| Parameter | Donepezil | Tacrine | Rivastigmine | Galantamine | ||
| Tmax (hr) | ||||||
| Cmax (ng/ml) | ||||||
| Bioavailability (%) | ||||||
| Protein Binding (%) | ||||||
| T1/2 (hr) | ||||||
| AUC (ng/ml/hr) | ||||||
| IC50 (nM) | ||||||
| Equivalent LDL Reduction Dosage (mg) | ||||||
| Metabolism | ||||||
References
